| |
For Immediate Release
For more information, contact:
Cheri
Winchester 636.530.1235 x 223
cwinchester@commongroundpr.com
Envisioneering Introduces New Prostate Cancer Treatment Technology to Europe
St. Louis, Mo. and Veendendaal, Netherlands (January 25, 2008) – Envisioneering
Medical Technologies, located in St. Louis, signed an exclusive European
distribution agreement with Netherlands-based Isodose Control. The
deal combines Isodose treatment planning software with TargetScan’s
precision biopsy and seed placement.
The distribution agreement allows European brachytherapists and radiation oncologists
for the first time to access TargetScan technology, a tool that supports more
accurate radiation delivery to the prostate gland according to clinical research. Patients
benefit by receiving accurate, nerve-sparing treatments for improved outcomes
with reduced treatment side effects such as impotence and incontinence.
“Through this agreement we will configure TargetScan to work with Isodose
Control’s treatment planning software, thereby placing new capabilities
into the hands of physicians to aid in their fight against prostate cancer,” said
Robert G. Mills, Envisioneering Medical Technologies president. “More
importantly, our partnership with Isodose means we can now deliver advanced prostate
cancer treatment technology to more patients around the globe.”
Unlike traditional devices, TargetScan supports brachytherapy treatments by providing
a 3-dimensional view of the prostate gland coupled with a stationary probe to
ensure accurate radiation delivery to pre-planned cancer targets. For patients,
the intended outcomes of TargetScan-supported brachytherapy treatments include
more accurate treatment delivery, reduced risk of side efforts and improved patient
comfort.
“Envisioneering’s newly developed TargetScan is the first static
probe to accurately visualize the complete 3-D prostate during the insertion
of the treatment applicator, offering unprecedented precision,” said Eric
van ’t Hooft, Isodose Control Chairman. “It is exactly what
has been missing in the past.”
About brachytherapy
Brachytherapy is a minimally invasive, nerve- and tissue-sparing
procedure that involves the use of radioactive seeds the size of
rice grains. Offered as an out-patient procedure, brachytherapy
treatments usually take 45 minutes to an hour to perform with most
patients returning to their normal activities within days. The
success rates of prostate brachytherapy have compared favorably
with success rates of radical prostatectomy and external beam radiation. In
comparison studies, prostate brachytherapy has shown to have a
favorable side effect profile when compared with other modalities. Clinical
studies have shown that prostate brachytherapy has a cure rate
of 94 percent for appropriately selected patients. For early
diagnosed cancer cases, brachytherapy is emerging as the treatment
of choice in Europe and a growing number of North American clinics.
About Envisioneering Medical Technologies
Envisioneering Medical Technologies, based in St. Louis, Mo., is
dedicated to developing, manufacturing and marketing proprietary
diagnostic and treatment technology for the physician community.
For more information please visit www.envisioneeringmedical.com.
About Isodose Control
Isodose Control was founded four years ago with the most experienced
brachytherapy engineering team in the world, responsible for at
least 80 percent of all brachytherapy systems used internationally
today. They have developed the latest brachytherapy equipment – the
combined products offer state-of-the-art and accurate treatments.
For more information please visit www.isodosecontrol.com.
###
|
|
